ToolGen, a gene editing company based in South Korea, has agreed to transfer its gene editing technology CRISPR-Cas9 to Nulla Bio, a crop genetic editing company. Through this agreement, Nulla Bio will gain the rights to use the technology to develop, produce, license, and sell functional crops, while ToolGen will receive royalty revenue. ToolGen is the exclusive owner of the original CRISPR-Cas9 patent in Korea, meaning that companies seeking to use this technology must go through ToolGen for a technology transfer. Nulla Bio, founded in 2022, has already secured gene editing technology that can modify the genome of crops, and is currently working on creating climate change-resistant and health-functional tomatoes and hemp. The transfer of the CRISPR-Cas9 platform will not only strengthen the business capabilities of ToolGen and Nulla Bio, but also support the global growth of domestic agri-biotech startups. This agreement highlights the continuing advancement of gene editing technology in agriculture and its potential to address challenges such as climate change and sustainable agriculture.